What Medications Treat Ataxia Muscle Stiffness & Bladder?
At a Glance
Muscle stiffness and bladder urgency in ataxia can be treated with targeted medications. Oral muscle relaxants like baclofen and Botox injections help manage stiffness, while bladder issues are typically treated with medications like mirabegron or localized bladder injections.
In this answer
3 sections
While physical therapy is a cornerstone of managing Autosomal Dominant Cerebellar Ataxia (ADCA), it is not the only tool available. Yes, there are specific, targeted pharmacological treatments to manage secondary symptoms like muscle stiffness, bladder urgency, and severe tremors [1]. Because ADCA affects multiple pathways in the brain and spinal cord, comprehensive care usually involves a combination of rehabilitation and medication to address both movement problems and these disruptive “non-motor” symptoms [2]. Because titrating these medications requires specialized expertise, it is highly recommended to work with a Movement Disorders Specialist or a neuro-urologist.
Relieving Muscle Stiffness (Spasticity)
Many people with ADCA experience spasticity—a continuous, involuntary tightening or stiffness of the muscles that can cause pain and restrict movement. This is particularly common in certain subtypes like SCA1 and SCA3 [3].
- Oral Muscle Relaxants: For generalized stiffness that affects the whole body or multiple limbs, oral medications like baclofen are considered standard therapies [4]. These medications work by signaling the nervous system to relax the muscles. However, they must be dosed very carefully; taking too much can cause widespread muscle weakness and drowsiness, which can worsen your balance and increase your risk of falls.
- Targeted Injections: If your stiffness is localized to a specific area (such as a severely tight calf or hand), your doctor may recommend localized injections of Botulinum toxin type A (commonly known as Botox) [5][6]. This treatment temporarily blocks the nerve signals that cause the muscle to contract, offering significant relief for specific muscle groups without causing whole-body drowsiness or weakness [7]. The effects typically wear off over time, so injections usually need to be repeated every 3 to 4 months.
Managing Bladder Urgency
Bladder issues, particularly neurogenic bladder (urinary urgency, frequency, or urge incontinence caused by nervous system damage), are incredibly common in ADCA and can severely impact your quality of life [8].
- Daily Medications: The first step is often taking oral medications designed to relax an overactive bladder. Antimuscarinic drugs (such as oxybutynin or tolterodine) are routinely used to increase the bladder’s storage capacity [9]. However, these can cause anticholinergic side effects like dry mouth, constipation, and, crucially, confusion or cognitive impairment. Because of this risk, your doctor might prefer beta-3 adrenergic agonists (such as mirabegron), which help reduce sudden urges to go while bypassing those cognitive side effects [10][11].
- Advanced Bladder Treatments: If oral medications are ineffective or cause intolerable side effects, urologists can use intradetrusor botulinum toxin A injections directly into the bladder muscle. This is a highly recognized and effective treatment for calming an overactive bladder that hasn’t responded well to pills [12][13][14].
Treatments for Severe Tremors
While poor coordination is the hallmark of ataxia, some individuals also develop severe kinetic tremors (shaking that occurs when you try to move your hand to a target) or postural tremors (shaking when holding a position against gravity).
- Subtype-Specific Medications: Depending on your genetic subtype, specific medications may be highly effective. For instance, 4-aminopyridine has recently shown success in improving symptoms in a newly identified subtype called SCA27B [15][16].
- Surgical Interventions: For disabling tremors that make feeding or dressing impossible and do not respond to medication, Deep Brain Stimulation (DBS) is sometimes explored as a last-resort option. DBS involves implanting a small electrode into a specific part of the brain (often the ventral intermediate nucleus, or VIM, of the thalamus) to interrupt abnormal tremor signals [17][18][19]. However, its results for cerebellar tremors are notoriously variable and less predictable than in conditions like Parkinson’s disease. Most importantly, DBS carries a specific risk of actually worsening underlying ataxia coordination or dysarthria (speech difficulty). It does not cure the underlying disease and requires careful evaluation of risks versus benefits by a specialized surgical team.
Common questions in this guide
How is muscle stiffness from ataxia treated?
Can medications for ataxia muscle stiffness make my balance worse?
What medications are used for bladder urgency in ataxia?
Are there treatments for severe tremors caused by ataxia?
What is a neurogenic bladder in ataxia?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific genetic subtype (if known), are there any targeted medications, like 4-aminopyridine, that might work best for my symptoms?
- 2.If we start a muscle relaxant like baclofen, how will we monitor my balance to ensure it doesn't increase my risk of falling?
- 3.Would I benefit from seeing a specialized neuro-urologist for my bladder urgency, and are there alternatives to pills if they cause side effects?
- 4.Are my tremors the type that respond well to medications, or are they primarily related to my ataxia?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (19)
- 1
A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice.
Marinina KS, Bezprozvanny IB, Egorova PA
Human molecular genetics 2024; (33(16)):1406-1419 doi:10.1093/hmg/ddae079.
PMID: 38727562 - 2
Cognitive, Emotional, and Other Non-motor Symptoms of Spinocerebellar Ataxias.
Lin CR, Kuo SH, Opal P
Current neurology and neuroscience reports 2024; (24(3)):47-54 doi:10.1007/s11910-024-01331-4.
PMID: 38270820 - 3
SCA1 patients may present as hereditary spastic paraplegia and must be included in spastic-ataxias group.
Pedroso JL, de Souza PV, Pinto WB, et al.
Parkinsonism & related disorders 2015; (21(10)):1243-6.
PMID: 26231471 - 4
Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.
Ertzgaard P, Campo C, Calabrese A
Journal of rehabilitation medicine 2017; (49(3)):193-203 doi:10.2340/16501977-2211.
PMID: 28233010 - 5
Research progress in the use of botulinum toxin type a for post-stroke spasticity rehabilitation: a narrative review.
Xu Q, Xiao H, Zhu Z, et al.
Annals of medicine 2025; (57(1)):2521427 doi:10.1080/07853890.2025.2521427.
PMID: 40551535 - 6
A Systematic Review and Comparative Analysis of Botox Treatment in Aesthetic and Therapeutic Applications: Advantages, Disadvantages, and Patient Outcomes.
Meretsky CR, Umali JP, Schiuma AT
Cureus 2024; (16(8)):e67961 doi:10.7759/cureus.67961.
PMID: 39328645 - 7
Longitudinal, Multi-Cycle Evaluation of Passive Function Improvement in People with Arm Spasticity Treated with Botulinum Toxin A.
Ashford SA, Buchwald K, Fheodoroff K, et al.
Toxins 2026; (18(1)) doi:10.3390/toxins18010051.
PMID: 41591197 - 8
Neurogenic bladder pathophysiology, assessment and management after lumbar diseases.
Hao J, Jiang J, Han Q, et al.
EFORT open reviews 2025; (10(3)):156-165 doi:10.1530/EOR-24-0087.
PMID: 40071973 - 9
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.
Fougere RJ, Currie KD, Nigro MK, et al.
Journal of neurotrauma 2016; (33(18)):1651-7 doi:10.1089/neu.2015.4278.
PMID: 26980078 - 10
The use of mirabegron in neurogenic bladder: a systematic review.
El Helou E, Labaki C, Chebel R, et al.
World journal of urology 2020; (38(10)):2435-2442 doi:10.1007/s00345-019-03040-x.
PMID: 31802206 - 11
Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Honda M, Yokoyama O, Takahashi R, et al.
International journal of urology : official journal of the Japanese Urological Association 2021; (28(9)):906-912 doi:10.1111/iju.14602.
PMID: 34075630 - 12
Correction of overactive bladder with botulinum toxin type A (BTX-A).
Grishin A, Spaska A, Kayumova L
Toxicon : official journal of the International Society on Toxinology 2021; (200()):96-101 doi:10.1016/j.toxicon.2021.07.005.
PMID: 34274378 - 13
Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity.
Joussain C, Phé V, Even A, et al.
European journal of physical and rehabilitation medicine 2017; (53(6)):991-997 doi:10.23736/S1973-9087.17.04978-4.
PMID: 29072045 - 14
Urologic applications of botulinum toxin.
King A, Quirouet A, Moore CK
Cleveland Clinic journal of medicine 2015; (82(7)):456-64 doi:10.3949/ccjm.82a.13166.
PMID: 26185945 - 15
Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B).
Abou Chaar W, Eranki AN, Stevens HA, et al.
Annals of neurology 2024; (96(6)):1092-1103 doi:10.1002/ana.27060.
PMID: 39263992 - 16
Spinocerebellar Ataxia Type 27B can be Suspected Based on Clinical Phenotype: The Massachusetts General Hospital Ataxia Center Experience.
Rettenmaier LA, Chen JYH, MacMore J, et al.
Cerebellum (London, England) 2025; (24(5)):133 doi:10.1007/s12311-025-01882-3.
PMID: 40679574 - 17
Neuronal activity and outcomes from thalamic surgery for spinocerebellar ataxia.
Hashimoto T, Muralidharan A, Yoshida K, et al.
Annals of clinical and translational neurology 2018; (5(1)):52-63 doi:10.1002/acn3.508.
PMID: 29376092 - 18
Long-Term Suppression of Disabling Tremor by Thalamic Stimulation in a Patient with Spinocerebellar Ataxia Type 2.
Isobe T, Sato H, Goto T, et al.
Stereotactic and functional neurosurgery 2019; (97(4)):241-243 doi:10.1159/000504062.
PMID: 31743916 - 19
Magnetic Resonance Imaging-Guided Focused Ultrasound Thalamotomy in Spinocerebellar Ataxia Type 12.
Purrer V, Upadhyay N, Pieper CC, et al.
Movement disorders : official journal of the Movement Disorder Society 2022; (37(4)):872-873 doi:10.1002/mds.28918.
PMID: 35050531
This page provides educational information about medications used for ataxia symptoms. Always consult a Movement Disorders Specialist or neuro-urologist before starting or changing any treatments.
Get notified when new evidence is published on Autosomal dominant cerebellar ataxia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.